Charles River Labs (CRL) PT Raised to $301 at Credit Suisse

Charles River Labs (CRL) PT Raised to $325 at JPMorgan, Following Earnings

February 17, 2021 12:27 PM EST

JPMorgan analyst Tycho W. Peterson raised the price target on Charles River Labs (NYSE: CRL) to $325.00 (from $280.00) while maintaining a Overweight rating.

... More

Charles River Laboratories (CRL) Tops Q4 EPS by 29c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus

February 17, 2021 7:11 AM EST

Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.29 better than the analyst estimate of $2.10. Revenue for the quarter came in at $791 million versus the consensus estimate of $756.86 million.

Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 Announces Definitive Agreement to Acquire Cognate BioServices, A Premier, Cell and Gene Therapy CDMO

GUIDANCE:

Charles River Laboratories sees FY2021 EPS of... More

Charles River Laboratories (CRL) to Acquire Cognate BioServices for $875 Million

February 17, 2021 7:07 AM EST

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million in cash, subject to customary closing adjustments. The transaction is expected to close by the end of the first quarter of 2021, subject to regulatory requirements and customary closing conditions.

James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, Cognate BioServices presents a unique opportunity to expand into a high-growth,... More